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Thienopyridines are a class of drug targeting the platelet adenosine diphosphate (ADP) 2 receptor. They signiﬁcantly reduce
platelet activity and are therefore clinically beneﬁcial in settings where platelet activation is a key pathophysiological feature,
particularly myocardial infarction. Ticlopidine, the ﬁrst of the class introduced to clinical practice, was soonchallenged and almost
completely replaced by clopidogrel for its better tolerability. More recently, prasugrel and ticagrelor have been shown to provide
a more powerful antiplatelet action compared to clopidogrel but at a cost of higher risk of bleeding complications. Cangrelor,
a molecule very similar to ticagrelor, is currently being evaluated against clopidogrel. Considering the key balance of ischemic
protection and bleeding risk, this paper discusses the background to the development of prasugrel, ticagrelor, and cangrelor and
aims to characterise their risk-beneﬁt proﬁle and possible implementation in daily practice.
1.Introduction
Ticlopidine, clopidogrel, and more recently prasugrel, con-
stitute the class of drugs called thienopyridines which is
characterized by the selective targeting of the adenosine
diphosphate (ADP) 2 receptor on the surface of platelets.
Blockageofthisreceptorresultsinreducedplateletactivation
which may have critical clinical beneﬁts in settings where
platelet activation is a key pathophysiological feature such
as in myocardial infarction. Historically, ticlopidine was the
ﬁrst member of this class. However, its not insigniﬁcant, risk
of neutropenia and thrombotic thrombocytopenic purpura
led to its predominant replacement by clopidogrel in routine
clinical practice [1].
Thienopyridines play a key role in the cardiovascular
arena.Theirapplicationcoversthewidespectrumofpatients
with stable angina (SA), acute coronary syndromes (ACSs),
and/or those undergoing percutaneous coronary interven-
tion (PCI). In these settings they reduce the restenosis rate,
the risk of thrombosis and major adverse cardiac events
[2, 3]. Perhaps clopidogrel administration alone is advisable
when there is contraindication to or aspirin intolerance
[4]. In acute myocardial infarction, for patients who have
undergone diagnostic cardiac catheterization and for whom
PCI is planned, clopidogrel should be started and continued
for at least 1 month after bare metal stent implantation
and for several months after drug-eluting stent implantation
up to 12 months in patients who are not at high risk for
bleeding [5]. In patients with unstable angina, clopidogrel
should be started on admission and administered for at
least 1 month, and, according to many experts, up to 9
months [6]. Overall, for those patient treated with PCI the
coadministration of aspirin (permanently) and clopidogrel
is mandatory. Following a bare metal or a drug eluting
coronary stent implantation, clopidogrel is administered for
at least 1 month and 1 year, respectively [7].
On the basis of ex vivo platelet function tests [8–12], it



















































Figure 1: Biochemical structures of thienopyridine and nonthienopirydine antiplatelet agents.
suboptimal antiplateletresponse toclopidogrel (“clopidogrel
nonresponders”) and, according to some pivotal studies [13–
15], these individuals should be considered as having a
higher risk of adverse clinical events in acute as well as
chronic coronary artery disease. This evidence drove the
searchformoreeﬃcaciousandreliableantiplatelettherapies.
A new thienopyridine agent Prasugrel (Eﬃent, Eli Lilly,
Indianapolis, IN) [16], and two cyclopentyl triazolo pyrim-
idines agents, ticagrelor (Brilinta, AstraZeneca, Wilmington,
DL) [17], and cangrelor (Cangrelor, The Medicines Com-
pany, Parsippany, NJ) [18, 19] have been introduced, aimed
at overcoming the drawbacks of their predecessors such as
variable antiplatelet eﬃcacy and risk of side eﬀects. Only the
ﬁrst has received approval from the FDA and the EMEA [20].
This paper will elucidate the evolution and possible
clinical application of these novel antiplatelet agents.
2. MechanismofActionofPrasugrel,Ticagrelor,
andCangrelor
Like other members of the thienopyridine class (Figure 1),
Prasugrel is a prodrug absorbed via the gut and is hydrolysed
into a thiolactibe (R-95913) via esterases in the gut wall,
liver, and plasma. This is then oxidised into the active
thiol metabolite R-138727 by the cytochrome p450 system,
mainly through the CYP3A and CYP2B6 isoenzymes. The
latter irreversibly binds the G-protein linked P2Y12 ADP
receptors on the platelet surface. An important diﬀerence
between the metabolism of prasugrel and clopidogrel is that
a signiﬁcant portion of the administered dose of clopidogrel
is deactivated in the early stages of its metabolism, resulting
in less availability of the active metabolite.
Ticagrelor (AZD6140) is the ﬁrst member of a new
class of orally active antiplatelet agents not requiring
metabolic activation. Ticagrelor is essentially an adenosine-
triphosphate (ATP) derivate (see Figure 1). Like the thien-
opyridine class of drugs, it inhibits the P2Y12ADP-receptor,
however, this inhibitory linkage is completely reversible.
Like ticagrelor, cangrelor has been derived from ATP
(see Figure 1) and, at present, it can be administered only
intravenously. After infusion, it reversibly binds the P2Y12
receptor with high aﬃnity without requiring a metabolic
activation.
3.PreclinicalStudies
The key pharmacodynamic and pharmacokinetic features
of the new antiplatelets agents are summarised in Table 1.
Studies in several animal models show that orally adminis-
tered prasugrel is completely absorbed from the gut and then
rapidly metabolised in the liver to the active thiol metabolite
withnoselectivetissueuptake.Thisactivehepaticmetabolite
has a stereoselective eﬀect and exerts a more potent and
dose-dependent inhibition of platelet activity compared to
ticlopidine and clopidogrel. Time from ingestion to the
maximal concentration of the active metabolite is about 30
minutes. Mean elimination half-life of the active metabolite
is 3.7 hours. Like other thienopyridines, the metabolites of
prasugrel are excreted via the kidney [21–28].Advances in Hematology 3











Prasugrel thienopyridines Oral Yes Yes No 3.7 Kidney
Ticagrelor Cyclopentyltria
olo-pyrimidines Oral No Yes Yes 6–12 Kidney
Cangrelor Cyclopentyltria
olo-pyrimidines Intravenous No No Yes 2.6–3.3 Kidney
Ticagrelor, the ﬁrst studied member of the class of
cyclopentyl triazolo pyrimidines, has been obtained by the
beta-gamma-methylene substitution of the ester linkage in
the triphosphate group of ATP. In contrast to natural ATP
which is rapidly inactivated by soluble nucleotidases, it is
relatively resistant to enzymatic degradation. Moreover, it
does not require any metabolic activation although an active
metabolite has been identiﬁed with quite similar features
and antiplatelet capacity thus participating in the overall
antiplatelet eﬀect. Peak plasma level of ticagrelor is reached
after 1.5–3 hours and the half-life is 6–12 hours, depending
on the dose [29, 30] and more than 70% is excreted via the
kidney.
In animal models, cangrelor inhibits ex vivo ADP-
induced platelet aggregation without prolonging the bleed-
ing times perhaps showing a fast restoration of platelet
reactivity at the end of the infusion. It rapidly reaches the
steady state concentration with a half-life of 2.6–3.3 minutes
[31, 32] and it is excreted via the kidney.
4.ClinicalStudies
4.1. Prasugrel. Prasugrel has been extensively investigated in
several phase II studies consistently showing that concen-
tration of the active prasugrel metabolite are higher, both
acutely and after 2 weeks of treatment, than the active
clopidogrel metabolite thus supporting the hypothesis that
the observed diﬀerences in pharmacodynamic eﬀects could
beduetodiﬀerencesinmetaboliceﬃciencyingeneratingthe
respective metabolites [33, 34].
The Joint Utilisation of Medications to Block Platelets
Optimally (JUMBO-TIMI 26) study reported an equivalent
risk of major bleeding events compared to clopidogrel thus
providing important safety data which facilitated further
evaluation of eﬃcacy of prasugrel [35, 36].
The large phase 3 Trial to Assess Improvement in Ther-
apeutic Outcomes by Optimizing Platelet Inhibition with
Prasugrel-ThrombolysisinMyocardialInfarction(TRITON-
TIMI) 38 trial [37] was a double-blinded study that ran-
domised 13608 patients with acute coronary syndromes
to aspirin and prasugrel (60mg loading dose followed by
10mg daily) or aspirin and clopidogrel (300mg loading
dose followed by 75mg daily). The composite endpoint
of cardiovascular death/myocardial infarction/stroke was
signiﬁcantly reduced in the prasugrel group, largely driven
by a lower rate of nonfatal myocardial infarction. No beneﬁt
in terms of mortality was observed while a signiﬁcant
increase in bleeding complications in the prasugrel group
was reported. According to subgroup analyses, patients
with diabetes mellitus, myocardial infarction, or complex
coronary lesions beneﬁted most from prasugrel treatment.
On the other hand, elderly patients, patients with a low body
weight (<60kg) or a previous history of stroke or transient
ischemic attacks did not beneﬁt [37].
In a recently published substudy (TRITON TIMI 38
substudy) which included 12844 patients undergoing coro-
nary stent implantation (bare metal or drug eluting stent),
prasugrel was associated with a signiﬁcantly reduced risk
of ischemic events and stent thrombosis, compared to
clopidogrel [38].
InaTRITON-TIMI38substudy,clinicalendpointsinthe
acute phase (within 3 days) and from the third day till the
end of followup have been compared. Of note, the loading
as well as the maintenance dose of prasugrel were superior
to clopidogrel for the reduction of ischemic events [39].
Moreover, the excess of bleeding in the former group was
related to the maintenance dose only. Recently, it has been
shown that Prasugrel is able to provide a net beneﬁt over
clopidogrel particularly in patients with diabetes mellitus,
that is, a reduction of ischemic events not counterbalanced
by an increased risk of major bleedings [40].
Prasugrel has also been shown to be superior to clopido-
grel in the setting of ST elevation myocardial infarction with
a durable beneﬁt up to 15 months [41].
On a pharmacodynamic/pharmacologic basis such a
superiority might be explained by the absence of any
interaction of the common functional cytochrome P450
genetic variants with drug metabolite levels and inhibition
of platelet aggregation [42].
We have recently showed, by means of an explorative
meta-analysis, that prasugrel compared to clopidogrel is
associated with a one-third higher risk and a two-fold higher
risk of major and minor bleedings, respectively [20].
4.2. Ticagrelor. The Dose Conﬁrmation Study assessing
antiplatelet Eﬀects of AZD6140 versus clopidogRel in non-
ST segment Elevation myocardial infarction (DISPERSE-
2) study [43] enrolled 990 patients admitted with non-
ST elevation acute coronary syndromes. Patients were allo-
cated, in a randomised fashion, to 300mg loading dose of
clopidogrel followed by 75mg daily for 3 months versus
ticagrelor 90mg twice daily for 3 months or 180mg twice
daily for 3 months. Twenty-ﬁve percent of the patients were
diabetic while a diagnosis of previous myocardial infarction4 Advances in Hematology
was present in about 24% of the cases. With respect to the
primary endpoint, the cumulative rate of major and minor
bleedings, no signiﬁcant diﬀerences were found between
the two doses of ticagrelor versus clopidogrel while a trend
in favour of ticagrelor was seen according to the risk of
myocardial infarction.
The Platelet Inhibition and Patient Outcomes (PLATO)
trial [17] was a large multicenter randomised controlled
trials that randomised more than 18000 patients with
ST elevation as well as non-ST-elevation acute coronary
syndromes. Patients were allocated to either clopidogrel
300mg (600mg in 19.6% of the cases) loading, then 75mg
daily for 9 months or ticagrelor 180mg loading, then 90mg
twice daily for 9 months. Twenty-ﬁve percent of the patients
were diabetic while a diagnosis of previous myocardial
infarction was present in about 21% of the cases. Ticagrelor
was associated with a signiﬁcantly lower risk of the primary
endpoint (composite of cardiovascular death, myocardial
infarction, or stroke) while no diﬀerences were seen in the
rates of major bleeding.
4.3. Cangrelor. The CHAMPION PCI study [18]w a sar a n -
domized, double-blind, double-dummy, active-control trial
comparing cangrelor with 600mg of clopidogrel in patients
with acute coronary syndromes undergoing PCI. Within 30
minutes of PCI, all patients received either cangrelor (in an
intravenous bolus of 30µg per kilogram of body weight and
an intravenous infusion of 4µg per kilogram per minute)
or a placebo bolus and infusion. Patients received 600mg
of clopidogrel (in four 150-mg capsules) or placebo at the
time of infusion. To allow the transition from intravenous
cangrelor to oral clopidogrel, patients received another four
capsules(eitherclopidogrel inpatientsreceivingcangreloror
placebo in patients receiving clopidogrel) at the discontinua-
tion of the study drug infusion.
A t4 8h o u r sa sw e l la sa t3 0d a y s ,c a n g r e l o rw a sn o ts u p e -
rior to clopidogrel with respect to the primary composite
endpoint (death from any cause, myocardial infarction, or
ischemia-driven revascularization) while, with respect to the
risk of major haemorrhage, cangrelor was associated with a
non statistically signiﬁcantly higher risk.
In the CHAMPION PLATFORM [19], patients under-
went randomization according to a double-blind, placebo-
controlled, double-dummy design to receive either cangrelor
(bolus of 30µg per kilogram of body weight followed by
infusion of 4µg per kilogram per minute) or a placebo
bolus and infusion “for the duration of the PCI procedure”,
with a minimum infusion duration of 2 hours and a
maximum of 4 hours. Patients in the cangrelor group
received 600mg of clopidogrel after the end of the cangrelor
infusion, and those in the placebo group received 600mg
of clopidogrel at the end of the procedure. Cangrelor
was not superior to placebo in reducing the primary
endpoint (death, myocardial infarction, or ischemia-driven
revascularization at 48 hours). The prespeciﬁed secondary
endpoints of stent thrombosis and death were lower in the
cangrelor group, with no signiﬁcant increase in the rate of
transfusion.
These two trials have been conducted and published in
parallel. Of note, at the 70% interim analysis, the interim-
analysisreviewcommitteereportedthattheestimatedcondi-
tionalpowerofCHAMPIONPCItodemonstratesuperiority
was low. However, in the absence of safety concerns, the
executive committee and sponsor elected to continue the
CHAMPION PCI trial until the CHAMPION PLATFORM
underwent its 70% interim analysis. At that time, the
interim-analysis review committee and the data and safety
monitoring board reported that the estimated conditional
power in CHAMPION PLATFORM was also low and
recommended discontinuation of enrolment into both trials.
Overall, these two trials do not support the imple-
mentation of cangrelor in routine practice, however, a
third trial (BRIDGE: Maintenance of Platelet inihiBition
With cangRelor After dIscontinuation of ThienopyriDines
in Patients Undergoing surgery, http://clinicaltrials.gov/ct2/
show/NCT00767507) is still ongoing aiming at investigating
the possible protective role of cangrelor in patients who
discontinue antiplatelet agents waiting for heart surgery.
4.4.ArePrasugrelandTicagrelorReadyforPrimeTime? Being
more potent and reliable in its antiplatelet eﬀect, when
administered in combination with aspirin to patients with
ACS undergoing PCI, prasugrel reduced both ischemic coro-
nary events and the incidence of coronary stent thrombosis
compared with the combination of aspirin and clopidogrel.
More powerful antiplatelet activity comes at a cost of
higher risk of major bleeding, thus an accurate selection
of those patients with a favourable risk/beneﬁt proﬁle is
mandatory. This selection is even more important when
considering that it has been compared against clopidogrel
in an unselected population with respect to clopidogrel
responsiveness. The assessment of the latter would imply
a consensus over the right tool to measure the residual
platelet activity and the exact timing. Moreover, in order
to standardise the bleeding risk it should be consensually
adopted one of the several bleeding risk score currently
available [44–47].
Prasugrel has already received approval from EMEA
and FDA [20] and it is clearly a very promising drug but,
consistent with any other new tool, a reasonable enthusiasm
should always be balanced with objective analyses.
Ticagrelor was associated with a much higher incidence
of dyspnea as compared with clopidogrel in PLATO (14.2%
of patients versus 9.2%; P<0.001), something that had
beenobservedinearlierphase2trialswiththeinvestigational
agent.
However, most episodes lasted less than a week and dis-
continuation of the study drug because of dyspnea occurred
in 0.9% of patients in the ticagrelor group. In terms of other
side eﬀects, Holter monitoring did detect more frequent
ventricular pauses during the ﬁrst week in the ticagrelor
group than in the clopidogrel group, but such episodes
were infrequent at 30 days and were rarely associated with
symptoms. There were no signiﬁcant diﬀerences in the rates
of clinical manifestations of bradyarrhythmia between the
two treatment groups.Advances in Hematology 5
Ticagrelor has been deﬁned as a prospective “blockbuster
drug”: in 2009, clopidogrel was the second-biggest-selling
drug in the world, with global revenues of more than $8
billion although generic versions of clopidogrel are already
available in Europe and are expected to appear in the US
within a few years. Considering the high number of patients
“clopidogrel nonresponders”, these people likely represent
the initial target for newer antiplatelet drugs.
The potential availability of three agents, clopidogrel,
prasugrel, and ticagrelor, for antagonizing platelet ADP
receptors would probably give a real chance to tailor
antiplatelet therapy.
A speciﬁc setting in which ticagrelor may be preferred
could be in patients whose coronary anatomy is unknown
and for whom a CABG procedure is deemed probable. And
if patients who are receiving clopidogrel or prasugrel need
elective surgery, it would seem reasonable to switch them
to ticagrelor ﬁve to seven days before surgery because of its
reversible platelet inhibition.
However, like prasugrel, the use of ticagrelor should
probably be avoided in those with a history of stroke or
transient ischemic attack and in those with a high risk of
bleeding. Given concerns over dyspnea, ticagrelor should
also be avoided in those with chronic obstructive pulmonary
disease, bradyarrhythmias unprotected by pacemakers or a
history of syncope.
Lastly, for all remaining patients with ACS, either
ticagrelor or prasugrel might be the right option.
While waiting for speciﬁcally designed trials, data from
indirect comparison of prasugrel and ticagrelor showed that
similar eﬃcacy and safety have to be acknowledged, but
prasugrel appeared more protective from coronary stent
thrombosis, while causing more bleedings [48].
5. Conclusion
The introduction of generic clopidogrel will probably make
clinical decision making even more complicated. In the
world of multiple new antiplatelet agents, considering both
the need for ischemic protection and the hazard of bleeding
will be crucial.
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